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ABSTRACT 
 
 This project details transgenic animal technology, applications, ethics and legalities, as an 
example of technology’s impact on society.  A transgenic animal has been genetically engineered 
to incorporate a foreign gene. Transgenic animals can be used as disease models, transpharmers, 
xenotransplanters, food sources, and other biological models. Although transgenic animals have 
clearly been documented to benefit society, this technology must weigh these benefits against the 
potential detriments to the animals or the environment.  
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PROJECT OBJECTIVES 
 
The objective of this project was to examine transgenic technology as an example of the 
effects of technology on society.  The first chapter details the various techniques used to create 
transgenic animals. Chapter two describes the applications of transgenic technology.  Chapters 
three and four examine the ethical and legal issues that stem from this controversial topic.  This 
report aims to provide the information on transgenic animals that is needed for readers to draw 
their own conclusions on this topic.  
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CHAPTER-1: TRANSGENIC ANIMAL TECHNOLOGY 
Rebecca Cunningham 
 
A transgenic organism is an organism that has been genetically engineered to incorporate 
a foreign gene.  Examples of transgenic organisms include mammals, fish, plants, bacteria and 
viruses. Transgenic animals include disease models designed to aid our understanding of human 
diseases, or transpharmers designed to produce life-saving drugs in their milk.  Transgenic 
technology has the potential to save millions of lives by revolutionizing modern medicine and 
agriculture. Although they have been engineered to benefit society, some types of transgenic 
animals suffer, so society must weigh the benefits against the detriments to the animals.  The 
purpose of this chapter is to discuss transgenic technology and how such animals are created. 
Transgenic animals are created using recombinant deoxyribonucleic acid (rDNA) 
technology to insert foreign DNA into the animal’s genome (Transgenic Mouse, 2005). 
Pronuclear manipulation and embryonic stem (ES) cell manipulation are the two major 
techniques used to engineer these animals, but before discussing those techniques, the entire 
process manipulates the molecule of life, DNA. 
 
Transgenic History 
 The first transgenic organism was created in 1973 by Stanley N. Cohen and Herbert W. 
Boyer (Cohen et al., 1973), who were able to construct a new functional plasmid species in vitro 
and insert it into an E. coli. Two years later, in February 1975, the Asilomar Conference on 
recombinant DNA molecules was held in Pacific Grove, California, to assess the risks associated 
with recombinant DNA research and recommend safety procedures and guidelines (Berg et al., 
1975). These procedures also helped prevent and contain biohazards. In the United States, the 
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National Institutes of Health allowed rDNA research to continue under strict guidelines. In 1974, 
the world’s first transgenic animal was created containing SV40 viral DNA inserted in a mouse 
genome, although the rDNA was not expressed in this instance (Jaenisch and Mintz, 1974; 
Transgenic Mouse, 2005).  In 1982, the world’s first expressing transgenic animal was created, 
an oversized mouse containing a growth hormone gene under the control of a metallothionein 
promoter (Palmiter et al., 1982). 
 
DNA 
 Deoxyribonucleic Acid (DNA) is often called the blueprint of life because it contains the 
instructions necessary for the construction of cellular components, including ribonucleic acid 
(RNA) and protein. DNA, RNA and protein are the three main macromolecules essential for all 
known forms of life (Campbell et al., 1999). Genes are the segments of DNA that contain 
inherited information. A genome is an organism’s unique and complete set of genes (Griffiths et 
al., 2008). 
 DNA is a polymer composed of two nucleotide chains (Figure-1). Each nucleotide chain 
has a backbone made from the sugar (deoxyribose) and phosphate.  DNA contains four different 
kinds of nitrogenous bases: adenine (A), thymine (T), guanine (G), and cytosine (C).  DNA 
forms a double helix that is held together by the base pairing of A with T, and G with C. Proteins 
are synthesized through the transcription of DNA (the synthesis of mRNA) followed by 
translation (the synthesis of protein) (Griffiths et al., 2008). 
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Recombinant DNA Technology Overview 
Recombinant DNA (rDNA) represents a new strand of DNA created by combining two 
or more strands of DNA.  rDNA technology is sometimes referred to as cut-and-paste technology 
because DNA is essentially “cut” using restriction enzymes and then “pasted” and sealed 
together using DNA ligase (Figure-2).  rDNA is sometimes referred to as chimeric DNA 
because it typically contains DNA from two different species. rDNA technology is used to 
identify, isolate, manipulate, and re-express genes from a given host (Carroll, 1993).  
rDNA is usually inserted into a vector system (plasmid, virus, cosmid, or artificial 
chromosome) to allow the successful propagation of the DNA in a host organism. The most 
commonly used vector is the plasmid. Plasmids are extra-chromosomal circular DNA found in 
bacteria (Cohen et al., 1973). The transfer of foreign DNA into a host cell is called 
Figure-1:  Double Helical Structure 
of DNA.  DNA is a double helix 
composed of two strands of 
deoxyribose sugar alternating with 
phosphate (gray), and four 
nitrogenous bases (shown in color) 
(Jones, 2002).  
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transformation in bacterial cells, and transfection eukaryotic cells. Transduction is the transfer of 
DNA by a viral vector or cosmid (Carroll, 1993). 
 
 
 
 
 
 
 
 
 
Methods for Creating Transgenic Animals 
Transgenic animal technologies have come a long way since the creation of the first 
transgenic mouse in 1974 (Transgenic Mouse, 2005). Many procedures have been developed to 
increase the efficiency of this generally inefficient process. The three main ways of producing 
transgenic animals are pronuclear manipulation, embryonic stem (ES) cell manipulation, and 
nuclear transfer (Figure-3). 
Figure-2: Overview of 
rDNA Technology.  A 
diagram of the steps 
used to create a 
recombinant organism 
(Carroll, 1993). 
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Pronuclear Manipulation 
 The pronuclear microinjection is the most reliable and common method for making a 
transgenic animal (Figure-4). However, the world’s first transgenic mice (Jaenisch and Mintz, 
1974) were not created by this method.  The first transgenic mice created using pronuclear 
microinjection were created by Gordon and colleagues in 1980 (Gordon et al., 1980).  The 
pronuclear microinjection technique begins by first preparing the rDNA as described previously.  
Eggs are harvested from super-ovulated animals and are fertilized in vitro. The eggs are taken 
prior to the first cell division while the two pronuclei are still present prior to zygote formation. 
The male pronucleus is typically selected for microinjection because of its larger size. The rDNA 
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vector is placed in a syringe and is then microinjected into the pronucleus (Transgenic Animals, 
2003).  
  
 
 
 
 
 
 
 
The microinjected embryo is usually cultured for 5-7 days to increase its vigor. Once the 
embryo reaches the blastocyst stage in vitro, it is implanted into a pseudopregnant female. A 
pseudo-pregnant female is a female that has been mated with a vasectomized male mouse to 
prepare the female for pregnancy (Gordon et al., 1980).  
 Unfortunately, with this technique, the incorporation of the transgene into the genome is 
a random process, so sometimes the transgene incorporates into an inactive area of the 
chromosome and is not expressed.  However, if the transgene is incorporated into an active 
region of the host chromosome, then all of the animal’s cells will express the transgene. Cells 
from the pups are screened to confirm the presence of the transgene. DNA pronuclear injection 
creates pure transgenic animals unlike ES cell manipulation which creates chimeras (Transgenic 
Animals, 2003).  
Figure-4: Pronuclear 
DNA Microinjection. 
A mild suction pipette 
(left) is used to hold the 
egg in place while the 
glass micropipette  
(right) microinjects the 
rDNA into pronucleus 
(Fässler, 2004). 
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 Other techniques exist for inserting DNA into pronuclei, including electroporation, 
retroviral infection, and sperm-mediated DNA transfer (Primrose and Twyman, 2006), but 
pronuclear microinjection remains the most reliable and popular technique. 
 
Embryonic Stem Cell Manipulation 
 Embryonic stem (ES) cells have the ability to develop into all of the tissues found in the 
developing embryo. The contribution of these undifferentiated ES cells to the germline was first 
demonstrated in 1984 (Bradley et al., 1984). ES cells are found in the inner cell mass of the 
blastocyst. ES cells can be grown into ES cell lines, genetically manipulated, and re-implanted 
into a blastocyst to create transgenic animals (Figure-5).  Because some of the blastocyst ES 
cells represent the original non-transgenic cells, the animals created using this technique are 
chimeras, not pure transgenic animals, so further breeding of the offspring is required to produce 
pure transgenic animals (Garvin et al., 1998).   
  
 
 
 
 
 
 
 
 
 
Figure-5: ES Cell Microinjection. 
Overview of the steps taken to produce a 
transgenic mouse by ES cell manipulation 
(Garvin et al., 1998). 
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 ES cell manipulation begins with the creation of embryo by in vitro fertilization (IVF). 
The embryo is grown for 5-7 days until it reaches blastocyst stage, then ES cells are harvested 
from the inner cellular mass. The ES cells are cultured, and the transgene is introduced using 
microinjection, viruses, electroporation, or chemical transfection. The ES cells are then screened 
to determine which ES cells contain the transgene (Transgenic Animal Science, 1991). The 
positive ES cells that contain the transgene are inserted into the inner cellular mass of a new 
blastocyst, and then the manipulated embryo is inserted into the uterus of a pseudo-pregnant 
host. The offspring are screened to determine which of the offspring are heterozygous for the 
transgene and then two heterozygous animals are bred to create an animal that is homozygous for 
the transgene (Transgenic Animals, 2003).  
One advantage of ES cell manipulation is that ES cells allow the use of homologous 
recombination to target where the transgene is inserted in the host’s genome. In homologous 
recombination, regions of host DNA are engineered to flank the transgene.  Once the rDNA is 
inserted into the ES cell, during normal DNA replication and cell division, the homologous DNA 
regions exchange between the rDNA and the host chromosome, targeting the transgene to the 
site.  So transgenes can be inserted into active areas of the chromosome.  The combination of ES 
cell pluripotency, tolerance of in vitro cell manipulation, and capacity for homologous 
recombination make ES cells an excellent method for creating transgenic animals (Primrose and 
Twyman, 2006). ES cell manipulation has been successful in creating transgenic mice but has 
not been used to create other larger mammals (Garvin et al., 1998).  
 
 
 13 
Somatic Cell Nuclear Transfer Technology 
 In 1996, somatic cell nuclear transfer (SCNT) technology was used to clone Dolly the 
sheep using six year old cells from a sheep’s udder (Campbell et al., 1996). The world’s first 
transgenic lamb, Polly, was also created using SCNT.  Polly was born in 1997 and contained the 
human gene for blood clotting factor IX.  Polly’s birth proved that creating transgenic animals by 
SCNT could be successful (Galvin et al., 1998). 
 SCNT is performed by removing the nucleus of an unfertilized egg cell and replacing it 
with the nucleus from a somatic donor cell (usually a skin fibroblast cell). To make a transgenic 
animal, the nucleus is microinjected with transgenic DNA prior to inserting the nucleus in the 
egg.  In order to produce a viable embryo the donor cell genome must be complete, and the egg 
must be treated with a drug to prevent the extrusion of any DNA in a polar body. An electric 
current is used to fuse the donor nucleus with the egg cell and to cause the egg cell to divide. The 
embryos are then implanted into surrogate mothers. The SCNT technique produces transgenic 
animals in which every cell contains the transgene. One advantage of nuclear transfer is that the 
gender of the transgenic animal is predetermined, as it will match the sex of the donor of the 
somatic nucleus (Garvin al., 1998).  
 
Assays for Screening Transgenic Animals 
 Regardless of which process is used to create transgenic animals, the process in 
inefficient, and most pups are born non-transgenic.  So, the pups must be screened to determine 
which ones took up the transgene.  ES cell manipulation requires that the embryos be screened 
for the transgene prior to insertion into the blastocyst and then into the foster mother. There are a 
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variety of screening tests commonly used including: PCR, Southern blotting, Western blotting, 
and enzyme linked immunosorbant assay (ELISA). 
 
PCR and Southern Blot Tests 
 Once a potential transgenic animal is born, for mice a short section of tail is taken for 
analysis.  DNA is isolated from the tissue, then screened using the polymerase chain reaction 
(PCR) technique, or the Southern blotting technique. PCR is used to amplify targeted DNA in 
vitro through a series of polymerization cycles. PCR depends on three temperature dependent 
steps:  template DNA denaturation, primer-template annealing, and DNA synthesis by a 
thermostable DNA polymerase (Rychlik et al., 1990).  If the primers are designed against the 
transgene, the amplification of a band during PCR indicates the presence of the transgene in the 
host DNA. 
 Southern blotting uses restriction enzymes to cut the purified DNA. The DNA fragments 
are then separated using gel electrophoresis, blotted to a membrane, then exposed to a 
radiolabeled complement probe of the transgene.  X-ray film is used to visualize the radioactive 
probe.  Southern blotting is used to determine the number of copies and even the location of the 
transgene. 
 
Western Blot Test 
 Western blotting is very similar to southern blotting, except in this case cellular proteins 
are separated by electrophoresis. The proteins are blotted to a membrane, and hybridized to an 
antibody against the transgene.  If the transgenic protein is present, the antibody binds the 
membrane.  That antibody can be located using a secondary antibody conjugated to a marker 
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enzyme that forms a color when reacted with substrate.  The difference between Western blotting 
and Southern blotting is that the former measures expression of the transgene, while the latter 
measures integration of the transgene (Carroll, 1993). 
 
Enzyme Linked Immunosorbant Assay (ELISA) 
 ELISA is a biochemical technique used to determine the presence of the transprotein in a 
fluid like blood or milk. It is a relatively quick and simple method that can be used to quantify 
the amount of transprotein in a sample. A well in a microtiter dish is coated with antibodies 
against the transprotein. A test solution (blood or milk) is added to the well, and if the 
transprotein is present it will be captured by the antibodies and retained in the well during a 
subsequent wash.  Then a secondary antibody is added to detect the captured transprotein.  In 
between each step the well is rinsed with a mild detergent solution to remove all unbound 
proteins. The remaining protein in the well is used to determine the quantity of transprotein in 
the original test solution sample (Garvin et al., 1998). 
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CHAPTER-2: TRANSGENIC APPLICATIONS 
Rebecca Cunningham 
 
 Transgenic animals have many applications in modern science and medicine.  Transgenic 
animals are divided into five classes based on their purposes. These classes are disease models, 
transpharmers, xenoplanters, food sources, and biological models.  The purpose of this chapter is 
to describe and provide examples of each class of transgenic animal.  This chapter will provide a 
background on transgenic applications and benefits to society that will serve as an introduction to 
chapter-3 on transgenic ethics. 
 
Disease Models 
 Transgenic disease models are animals that have been genetically altered to express some 
aspect of human disease.  Disease models allow scientists to develop potential therapies without 
the use of human subjects. Once a treatment is successful in animal models, it can be approved 
for clinical testing in humans. Three successful transgenic disease models that are discussed in 
this chapter are AIDS mouse, Alzheimer’s mouse, and Oncomouse.  
 
AIDS Mouse 
 Acquired Immune Deficiency Syndrome (AIDS) is the final stages of infection by the  
retrovirus Human Immunodeficiency Virus (HIV).  AIDS is a worldwide pandemic.  The CDC 
estimates that there are more than one million Americans currently living with HIV.  In 2009 in 
Worcester, MA, 42 people were diagnosed with HIV, bringing the total of people living with 
HIV in our city to 1,375 people (CDC, 2009). There is no known cure or vaccine for AIDS. 
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 Animals are not normally susceptible to HIV infection and AIDS.  Monkeys can be 
infected with the Simian Immunodeficiency Virus (SIV) which is the monkey equivalent to HIV. 
Monkeys are expensive and cannot be reliably infected with HIV.  Transgenic AIDS mice and 
rats were developed as alternative, less expensive, AIDS models.  
 The first AIDS mouse was not transgenic; it was a SCID mouse, meaning it lacked an 
immune system.  Human lymph nodes were implanted into the SCID mouse.  The implanted 
human tissue was then infected with HIV (Namikawa et al., 1988).  CD4 and CKR5 co-receptors 
are responsible for the attachment of HIV to human cells. One early transgenic AIDS mouse 
contained the gene for HIV tat, a viral protein that is needed for HIV infection (Vogel et al., 
1988).  This early AIDS mouse developed signs of Kaposi’s sarcoma, a common condition seen 
in people infected with AIDS.  
 Mice are not the only animals used for HIV and AIDS research. Other animals including, 
monkeys, rats, cats, rabbits, and Drosophila have been used as AIDS models.  Mice make good 
models because they are cheap, and much is already known about their genes. Animal models 
provide important information about the life cycle of HIV and can be used to try and develop 
treatments and vaccines.  
 
Alzheimer’s Mouse 
 Alzheimer’s disease (AD) is an incurable, degenerative, terminal illness. The exact cause 
of AD is unknown.  AD is the most common form of dementia, and is characterized by the 
development of amyloid plaques in the brain.  Amyloid plaques are composed of amyloid β-
peptide (Aβ), a fragment of the β-amyloid precursor protein (APP) (Games et al., 1995). 
Neurofibrillary tangles are twisted strands of tau protein found in dead and dying nerve cells. 
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Plaques and tangles are found mainly in the cerebral cortex and hippocampus, the parts of the 
brain responsible for memory and thought.  AD usually affects people over 65 years old. 
Sometimes AD is early-onset affecting people as young as 30 years old (Alzheimer’s, 2011).  
 The world’s first Alzheimer’s mouse was genetically engineered to incorporate an APP 
mutation at Worcester Polytechnic Institute in Worcester, Massachusetts, and colleagues at the 
former Transgenic Sciences Inc. (Games et al., 1995).  Under the control of a PDGF-β promoter, 
the neurotoxic Aβ appeared in the same parts of the Alzheimer’s mouse brain as it did in human 
brains. This first mouse model was used by Elan Pharmaceuticals (South San Francisco, CA) to 
create an AD vaccine, an antibody against Aβ (Schenk et al., 1999).  The AD vaccine was 
effective in removing amyloid plaques in AD mice. Unfortunately, the first set of human clinical 
trials were not successful, and were stopped after the vaccine caused swelling of the central 
nervous system (Herper, 2002), however Elan has initiated a newer clinical trial using a second 
generation vaccine against a different portion of Aβ that does not appear to cause brain swelling.  
Phase II trials of Wyeth and Elan’s Alzheimer’s vaccine ACC-001 were also halted after 
participants began to develop skin legions (McGuire, 2008).  
 
Oncomouse 
 Oncomouse (Figure-1) was the first patented transgenic animal. Oncomouse was created 
by Philip Leder and Timothy Stewart of Harvard University in 1984.  The term “Oncomouse” 
actually refers to 13 different strains of mice that were engineered to contain a human oncogene 
that causes tumor formation (Stewart et al., 1984). This disease model was created to study 
cancer formation and to screen anti-tumor drugs.  The patent for Oncomouse was filed in 1984 
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(Leder and Stewart, 1984).  Four years later Oncomouse became the world’s first patented 
transgenic animal on April 12, 1988.  
 
 
 
 
 
 
 
Transpharmers 
 Transpharmers are genetically engineered to produce a human pharmaceutical in their 
saliva, milk, urine, or blood.  Milk is the most common medium because the pharmaceuticals 
only have a small amount of contact with the animal’s bloodstream, so it has little effect on their 
physiology. The drug can be collected and purified without harming the animal. Cows, goats, 
sheep, pigs, rabbits, chicken, and mice have already been used as transpharmers (Genetic, 2011).  
 Herman the bull the world’s first transgenic cow was engineered in September, 1991, by 
Gen Pharm International of Mountain View, CA.  Herman had eight calves in Gen Pharm’s 
European Laboratory in Leiden, The Netherlands (Biotech, 1994). Herman was engineered to 
carry the human gene for lactoferrin by pronuclear microinjection. Lactoferrin is an iron rich 
protein that is important for human infant growth.  Cow milk and artificial formula do not 
naturally contain lactoferrin.  Herman’s female offspring produced lactoferrin in their milk 
(Brink et al., 2000).  
Figure-1: Oncomouse.  Harvard’s 
Oncomouse was created in 1984 by 
Stewart and Leder (Oncomouse, 
2011). 
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Transpharmers can be created using several approaches.  Herman was a lactoferrin 
founder bull used to create transgenic female offspring. Microinjection can also be directly used 
to create transgenic females. Nuclear transfer can also be used to create transpharmers. The 
nuclear transfer approach is popular because gender can be pre-selected, cutting down 
production time (Brink et al., 2000).  Figure-2 illustrates the three common methods for creating 
transpharmer cows. 
 
 
 
 
 
 
 
 
 
 
 
 
Xenotransplanters 
Xenotransplanters are animals that have been genetically modified to have organs that 
can be transplanted into humans. A xenotransplant is an organ that has been transplanted from a 
different species. Xenotransplanters are altered so that they do not express key foreign antigens 
Figure-2: Three Scenarios for Producing Transgenic Cattle Containing Recombinant 
Protein in their Milk. The figure shows the time lines in months for producing 100 kg of 
recombinant protein, assuming that a single cow produces 10,000 L of milk in an 8 month 
lactation period (Brink et al., 2000).  
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that cause immuno-rejection. There are currently 111,909 people on the United Network for 
Organ Sharing (UNOS) waiting list based on OPTN data as of August 23, 2011. The number of 
transplants performed is limited by a shortage of human organs and tissues. Xenotranplants are a 
promising alternative to human donors.  
The pig is the primary animal used for xenotransplant research. Pigs are used instead of 
primates because they are widely available and they are not endangered. The size and physiology 
of pig organs are similar to human organs.  Pigs have the sugar α-1,3-galactose (αGal) on the 
surface of their cells. αGal causes humans to reject pig organs. The enzyme α-1,2-
galactosyltransferase (GGAT1) produces αGal (Pearson, 2003).  Pigs have been genetically 
altered to knock out GGAT1, and the genetically modified organs had a much lower instance of 
rejection in monkeys than the unaltered organs (Pearson, 2003).  Porcine heart valves have been 
successfully transplanted into human hearts for years now, and soon this may extend to livers, 
kidneys, and lungs.  There are concerns about transplanting entire pig organs into humans; 
including the possibility that porcine viruses may cross the species barrier. But the risks could be 
minimized by pre-screening the pigs for known viruses. 
 
Food Sources 
 Transgenic animals have been created in an attempt to produce a new food source. By 
creating animals that grow larger without much food scientists had hoped to create a more 
efficient, cost effective, food source. Transgenic animals are not yet produced commercially as 
food sources because of ethical and safety concerns. They have only been created for research 
purposes.  
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Superpig 
 Superpig was created in an attempt to produce a fast growing, lean animal that consumes 
less food than normal pigs. The idea was to create a more feed-efficient food source.  Superpig 
was created by microinjecting a gene that expressed either bovine growth hormone or ovine 
growth hormone (Miller et al., 1989; Pursel et al., 1997). The rate of gain was increased by 15%, 
feed efficiency by 18%, and carcass fat was reduced by 80% (Rollin, 1996). Unfortunately, 
Superpig suffered life-shortening pathogenic changes, including kidney and liver problems. 
Superpig also exhibited lethargy, lameness, uncoordinated gait, bulging eyes, thickening skin, 
gastric ulcers, severe synovitis, degenerative joint disease, heart disease of various kinds, 
nephritis, and pneumonia (Rollin, 1996). Scientists decided to put a voluntary moratorium on 
transgenic experiments with growth hormones in mammals after Superpig suffered such 
debilitating symptoms.  
 
Superfish 
 A Superfish does not have the same ethical concerns as Superpig or other mammalian 
models.  AquAdvantage® Salmon (AAS) (Figure-3) was developed by AquaBounty 
Technologies in Waltham, Massachusetts (AquaBounty, 2011). AAS is an Atlantic salmon that 
contains a gene for Chinook salmon growth hormone. AAS is able to grow to market size in half 
the time it takes the Atlantic salmon. The Chinook salmon is the largest of the Pacific salmon. 
AAS is sterile to eliminate the possibility of accidental introduction into the wild (AquaBounty, 
2011).  
 The FDA decided to classify animals with genetically modified traits as veterinary drugs 
in 2009 (Merris, 2010). The Veterinary Medicine Advisory Committee (VMAC) will hold public 
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sessions to evaluate the potential benefits, safety concerns and environmental impact of 
genetically modified salmon.  A decision will be made regarding the approval of genetically 
modified salmon once the VMAC advises FDA’s Center for Veterinary Medicine (Merris, 2010).  
 
 
 
 
Transgenic Biological Models 
 Biological models are created to increase our knowledge about the function of protein by 
overexpressing the gene encoding that protein, or knocking it out. Transgenic biological models 
can help us learn more about the fields of biology and genetics. Examples of transgenic animals 
that have been created for this purpose include ANDi, Smart mouse, and Youth mouse.  
 
ANDi 
 The world’s first transgenic monkey was ANDi.  ANDi was one of three rhesus monkeys 
born that contained the transgene for the green fluorescent protein (GFP) in all tissues. These 
transgenic monkeys were produced by retroviral gene transfer into mature oocytes (Chan et al., 
2001).  A fraternal set of twins miscarried at 73 days and three males were born (including 
ANDi) from the 20 embryo transfers. The fraternal set of twins were confirmed to have carried 
the transgene by Southern blot analysis (Chan et al., 2001).  
Figure-3: AquAdvantage® Salmon. 
An Atlantic salmon  that contains the 
gene for Chinook growth hormone 
(Marris, 2010). 
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Smart Mouse 
 In 1999 researchers created smart mice that were genetically modified to have superior 
learning and memory. These mice were named Doogie, and were modified to over-express the 
NR2B transgene in the cortex and hippocampus, with little expression in the thalamus, brainstem 
and cerebellum (Tang et al., 1999).  Behavioral tests were administered to access learning and 
memory of the transgenic mice compared to their non-transgenic litter mates. The transgenic 
mice were found to learn faster and remember objects four to five longer than their normal litter 
mates (Harmon, 1999). 
  
Youth Mouse 
 There is a direct correlation between food consumption and life span across multiple 
species. αMUPA is a line of transgenic mice that eat ~20% less and live ~20% longer than the 
wild type (Miskin et al., 1999). The αMUPA mice exhibited a young look, even at old ages 
(Figure-4). Compared to the wild type mice, αMUPA mice had a lower body temperature. The 
spontaneous decrease in food consumption corresponded to a decrease in body temperature in 
αMUPA mice at all ages (Miskin et al., 1999). The homeostatic state of delayed aging can be 
investigated using this transgenic biological model.  
 
 
 
 
 
 
 
Figure-4: αMUPA and Wild 
Type mice. After 30 months 
αMUPA mice (right) still 
appear young compared to 
the wild type (left). 
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Chapter-3: Transgenic Ethics 
Andrew Reed 
 
Historically, all types of animals have gone through evolution that has changed their 
looks and properties.  Some change has been natural, while selective breeding has brought about 
other changes.  But with transgenic technology, animal properties can be exchanged between 
species.  Transgenic animals have already provided many benefits to humans including the 
production of drugs and food, the reduced need to use pesticides or herbicides, and a reduction in 
the overall number of animals used for scientific testing.  But just because we have the ability to 
create such animals, should we?  This chapter will investigate the ethics of transgenic animals, 
balancing the benefit to society against the detriment to the animals. 
 
Disease Model Ethics 
 Disease models are animals engineered to mimic specific aspects of human disorders for 
the purpose of studying disease formation or for testing potential therapies.  Examples of animals 
in this section (discussed in Chapter-1) are Alzheimer’s mouse, Oncomouse, and HIV mouse.  
Disease models are one of the most debated groups of transgenic animals, as they have strong 
benefits to society while the animals can suffer.  So the ethics of this group involves weighing 
the extent of medical information we can obtain to cure a disease versus how much the animal 
suffers.  The medical benefits are among the highest for any class of transgenic animal, as they 
give hope to some of the sickest people in the world.   
 Disease models are needed to help find cures for diseases.  When drug companies are 
testing a new drug, these drugs cannot be tested in humans until their relative safety is first 
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proven in animals.  So scientists use animals to make sure there are no drug side effects.  Some 
of these effects may only happen in a small percentage of the human population, but drug 
companies are not given permission to test high numbers of patients in phase-I clinical trials for 
safety, so they need to test fairly large numbers of mice.  But mice don’t get many human 
diseases in nature, so scientists must engineer them to mimic these diseases.  The animal testing 
in these situations is crucial if people want to eventually find the cures that they are looking for.   
Oncomouse has a huge benefit for medicine because it has taught scientists much about 
carcinogenesis (cancer formation), and has allowed drugs to be rapidly screened for fighting 
cancer.  But Oncomice can suffer, especially when the tumors are allowed to grow to the 
advanced stage.  As discussed in Chapter-4 on Transgenic Legalities, the probability that 
Oncomouse would help find a cure for cancer (and provide profit to its creators) was so high that 
Harvard Medical School and Dupont eventually received a patent on it.  The United States Patent 
Office in 1988 granted patent no. 4,736,866 to Harvard College claiming ‘a transgenic non-
human mammal whose germ cells and somatic cells contain a recombinant activated oncogene 
sequence introduced into said mammal…’ (Leder and Stewart, 1984).  The claim explicitly 
excluded humans, apparently reflecting the moral and legal concerns about patents on human 
beings, and about modification of the human genome” (WIPO Magazine 2006).  Although 
Oncomouse was later patented in Europe and Japan, it was denied in Canada, where the 
Canadian Supreme Court said, “A higher life form is not patentable because it is not a 
‘manufacture’ or ‘composition of matter’” (Check, 2002).  Following this case, ethical questions 
arose with respect to the question of suffering caused to the animal? (Check, 2002). 
 With respect to whether Oncomouse experiments should be continued, the author of this 
chapter believes that testing should be continued because there is much to be learned from them 
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about cancer formation.  Because the mice suffer with advanced tumor formation, pain killers 
should be mandated by institutional IACUC committees whenever possible, and the animals 
should be sacrificed before advanced tumor formation if the experiment allows that. 
 With respect to Alzheimer’s mouse, this mouse also provides a strong societal benefit.  The 
American Alzheimer’s Association predicts that over time the 5.4 million people that already 
have Alzheimer’s could grow to over 20 million over the next couple of decades.  The original 
creation of this mouse (Games et al., 1995) provided proof that the formation of neurotoxic Aβ 
initiates the disease.  And the mouse line was used by Elan Pharmaceuticals (South San 
Francisco, CA) to create the world’s first Alzheimer’s vaccine, initially tested in mice (Schenk et 
al., 1999), and later in human clinical trials (Elan, 2011).  Thus, this transgenic mouse serves as a 
good example for how using information gained from animals can be eventually applied to 
humans.  With respect to this line of experimentation, the author of this chapter believes that it 
should be continued.  The mouse line does not appear to suffer by any measurable criteria (there 
are only small behavioral alterations), yet it has already provided strong societal benefits. 
    
Transgenic Art Ethics 
  
 Should we be able to change the genes in animals to make them look “cool” or make it 
easier to identify the animals?  Should we be allowed to genetically engineer animals to 
aggressively occupy a niche in the ecosystem to destroy another invasive species?  There is little 
scientific knowledge to be made from making such animals, but such experiments are currently 
being done by private organizations.  The one that I found the most interesting is “Alba,” the 
rabbit that glows under UV light, designed by Eduardo Kac.  The rabbit is part of Eduardo Kac’s 
plan to create “transgenic art.”  This plan is a new way of humans interacting with animals and 
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transforming them solely for the purpose of art.  Kac is hoping that artists can create their own 
species of animals (Kac, 1998).  As expected, this line of experimentation came under strong 
attack because not only was there a plan in place if the animals escaped, but it really had no 
societal benefit.  The author of this chapter believes this is a “cool concept”, but since there is no 
medical benefit it should not be continued.  
 
Transpharmer Ethics 
Transpharming is the use of animals to create a life-saving pharmaceutical drug in the 
milk or blood.  Milk is the preferred site of production because the presence of the product has 
little effect on the animal’s physiology, and isolation of the drug does not harm the animal.  
Transpharmer animals include mice, cows, sheep, and goats.  The author of this chapter believes 
that this line of experimentation should be continued because of the medical benefits and lack of 
animal suffering.  
 
Xenotransplanter Ethics 
While it may sound strange to place an animal’s organ into a human, this may eventually 
turn out to be one of the best transgenic applications yet.  A girl in Mexico, after getting newborn 
pig cells, has not required any insulin or other drugs for her diabetes.  This procedure used a new 
technique which implanted two different types of cells, insulin producing β-cells and sertoli 
cells, which prevent other cells from attacking the implant.  This was the first xenotrasplant that 
lasted a long time.  This idea is not a new one, but has become more popular recently as more 
patients await organ transplants.  Pig hearts are now being used for heart transplants when human 
donors are not available (Leahy and LePage, 2002).  The pig heart valves seem to work 
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extremely well and have no diseases or medical malfunction. 
But some people are concerned with the possibility that pig viruses might jump species 
into their human host and cause disease.  Pigs are well known to carry influenza viruses that can 
infect humans (swine flu), and they can carry retroviruses.  So the author of this chapter agrees 
with scientists who argue that any pigs used for organ donation should be screened in advance 
for pig viruses that are known to cause diseases in humans. 
 
Transgenic Food Source Ethics 
Chapter-1 discussed examples of transgenic animals engineered for consumption.  In this 
category of transgenic animals, the ethics focuses on the benefit to mankind of helping alleviate 
hunger, versus the death of the animal to provide man’s food.  This debate is not specific to 
transgenic animals, but could be applied to any farm animal currently sacrificed for our food. 
One successful example of a transgenic food source is Aquabounty’s Superfish that 
grows to a larger size on less food.  This fish was designed for the aquaculture industry, and is 
near to receiving FDA approval as the world’s first transgenic animal for consumption (Marris, 
2010).  This fish will enable the aquaculture industry to raise larger fish cheaper.  The ethical 
question here is should we be changing the size of animals for our benefit.  In fact, mankind has 
been increasing the size and other desirable characteristics of livestock for generations by 
traditional breeding, so this debate is not new.  I feel the type of experimentation should 
continue, as it will eventually provide a crucial food source to third world countries that do not 
have access to much meat. 
Another example of a transgenic food source discussed in Chapter-1 was Superpig, who 
also grew to a large size faster than his non-transgenic littermates.  Although this animal is 
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similar to Superfish in that they both grow to large sizes, Superpig developed severe health 
problems, including severe arthritis and large tumors (Rollin, 1996).  The health problems 
became so bad the animal had to be euthanized, and scientists put in place a voluntary 
moratorium banning all growth hormone experiments in mammals. 
 
 
Scientific Model Ethics 
Transgenic scientific models are created to test the function of specific proteins in vivo by 
over-expressing them or under-expressing them, then assaying the changes to the animal.  These 
animals are a great help to the human community when trying to learn about the effects of 
specific proteins on the body, and are a huge help expanding what we know about genetics and 
biology.  For most of these models, the animals do not suffer, but some do not survive the altered 
gene expression patterns. 
 One example discussed in Chapter-1 was Doogie the Smartmouse.  This mouse was 
created by a Princeton scientist (Tang et al., 1999), who over-expressed the NR2B subunit of the 
glutamate receptor.  This subunit predominates when mammals are young and can learn more 
easily, so the hypothesis was that by over-expressing NR2B, the mice would learn faster, which 
they did.  This mouse was a breakthrough in memory research and revealed a common 
biochemical mechanism involving the glutamate receptor at the root of nearly all learning.  It 
shows that the brain uses the same basic mechanism even though parts of the brain deal with 
diverse types of information, such as sights, sounds, and touch (Harmon, 1999).  So it is now 
plausible to think that we could change the genetics of an animal to make them smarter.  So with 
respect to ethics, should we be thinking about engineering humans to make them smarter?  This 
is too large a jump for society to even consider now, but the author of this chapter believes that 
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Smartmouse provides an excellent example of how such animals can provide valuable scientific 
information without harming the animal.   
 
Chapter-3 Conclusions 
 It is the author’s conclusion that all categories of transgenic animals being tested are 
helpful to society.  The social benefit in my mind far outweighs animal sacrifice to save lives for 
cancer, Alzheimer’s disease, HIV, hunger, organ transplants, etc.  Millions of people dying every 
year because of these diseases, so further transgenic testing should be continued.  Having family 
members that have had cancer, I believe we should especially continue all cancer transgenic 
experiments, even if that includes the death of some of the animals.  When saving human lives, 
the benefits greatly outweigh the death of the mice. 
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Chapter-4:  Transgenic Legalities 
Andrew Reed 
 
The United States’ laws for allowing patents are challenging, but when trying to patent a 
life form these laws become even more challenging.  The purpose of this chapter is to discuss the 
patenting of transgenic animals, and whether such patents facilitate medical research or hinder it. 
 In the US, the definition of a patent is as follows, “any new and useful art, machine, 
manufacture or composition of matter, and any new and useful improvement on any art, 
machine, manufacture or composition of matter” (A Brief History, 2003).  The invention must be 
novel (not created before), and not obvious to most people in that field.  With respect to 
patenting life, the courts debated the phrase “composition of matter” and whether it applied to 
animals.  Before the first transgenic animal patent was awarded, the courts first had to approve a 
patent for a microbe in Diamond v Chakrabarty. 
 
Diamond v. Chakrabarty 
Dr. Chakrabarty was a microbiologist and one forefathers in the field of engineering 
microbes.  He engineered a Pseudomonas bacterium to be able to break down crude oil.  In 1972, 
he filed his patent with 36 claims related to “a bacterium from the genus Pseudomonas 
containing therein at least two stable energy-generating plasmids, each of said plasmids 
providing a separate hydrocarbon degradative pathway” (Diamond v Chakrabarty, 1980).  
“Chakrabarty’s patent claims were of three types: 1) process claims for the method of producing 
the bacteria (447 USC 306), 2) claims for an inoculum comprised of a carrier material floating 
on water, such as straw, containing the new bacteria, and 3) claims to the bacteria themselves 
(206 USC 196).  The patent examiner initially allowed the claims from the first two categories, 
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but rejected the claim for the bacteria. His decision rested on two grounds: (1) that micro-
organisms are “products of nature,” not composition of matter, and (2) that as living things they 
are not patentable subject matter under 35 USC §101 (Diamond v Chakrabarty, 1980).   
When Chakrabarty realized one of his claims was not going to be allowed, he filed an 
appeal.  He first relied on the legislative history of the 1930 Plant Patent Act, in which congress 
allowed patent protection to asexually produced plants.  But the Appeals Board said that US 
§101 was not envisioned to cover living microorganisms, so the Plant Patent Act was ruled 
outdated for this purpose.   If Chakrabarty wanted to get the appeal, he would have to find 
another case as precedent.   
Almost two years later, on May 20, 1976, the three-man Appeals Board conceded that 
Chakrabarty’s bacteria did not occur naturally, so were not products of nature, but it still upheld 
the rejection of the third claim on a new explicit ground -- that the bacteria were not patentable 
because they were living organisms (Kevles, 2002).  But after waiting five years from the start of 
the case, and being in several lawsuits to try to get the patent passed, MaLossi argued 
Chakrabarty’s case on December 5, 1977, and on March 2, 1978 the Court ruled three-to-two in 
Chakrabarty’s favor.  Judge Rich, speaking for the majority, saw only one issue --- the 
patentability of living organisms, and agreed to allow patents for microbes.   
This landmark case was cited considerably in the subsequent Oncomouse case for 
patenting animals, and is the reason that animals can now be patented.  
 
Animal Patents 
Following the Chakrabarty court case allowing the patenting of a living microbe, patents 
were filed in 1984 by Harvard and Dupont for Oncomouse (Leder and Stewart, 1984).  This 
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filing initiated fierce debate in the courts as to whether multicellular organisms including animals 
could be patented.  Finally, on April 21, 1987, about ten years after the case of Diamond v. 
Chakrabarty, the US Patent and Trade Office (PTO) released this statement: “The Patent and 
Trademark Office now considers non-naturally occurring non-human multicellular living 
organisms, including animals, to be patentable subject matter within the scope of 35 U.S.C. 101” 
(Patent and Trademark Office Notice, 1987).  The PTO statement opened the door for the 
Oncomouse case; the award given in 1988 was the first animal patented, and was the first patent 
allowed under the 1987 PTO ruling that animals could now be protected under the new patent 
law.  This case in the history of United States cases was one of the most complex and included 
several appeals, but was eventually passed and is now viewed by all people as a breakthrough 
case.   
Since the landmark Oncomouse court case, over 800 animals have been patented 
including birds, sheep, pigs, fish, horses, and chimps.  Not only are the animals themselves 
patented, but in some cases the award extends to include the process used to make the animal.  
The number of patents grew as the technology advanced (Environment News Service, 2000).  In 
2009, the US FDA published new simpler guidelines for patenting transgenic animals (FDA.gov, 
2009), and this makes it even easier to patent these animals today.  The new guidelines should 
make the filing and approval of animal patents much more routine, and make it easier for 
biotechnology companies to raise money if investors feel that patents likely will be awarded.  
 
Oncomouse In Canada 
 While the Oncomouse patent was awarded in the US, Europe and Japan, that was not the 
case in Canada.  In Canada the courts argue that life cannot be patented (Bird and MacOdrum, 
 39 
2008).  “In their ruling that a patent should not be granted for the mouse, the Canadian Court 
rejected the argument that the genetically engineered mouse constitutes either a “manufacture” or 
a “composition of matter” within the statutory definition of “invention” in the Canadian Patent 
Act.   Interestingly, the majority of the Supreme Court members accepted that the genetically 
altered egg obtained by injecting the oncogene into a fertilized egg satisfies the definition of 
“composition of matter”, but they still rejected the patent (Check, 2002; Barrigar 2008).  Canada 
remains the only country where Dupont applied for the Oncomouse patent where it was not 
awarded. 
 
Erythropoietin and the World-Wide Patent War 
 Erythropoietin (EPO) is a hormone that controls red blood cell production.  EPO patents 
are considered the most wanted patents in the world because of the billions in annual sales.  EPO 
patents are litigated in over 30 countries worldwide using powerful legal teams.  
“EPO, a glycoprotein, acts as a hormone that stimulates the production of red 
blood cells and is mainly produced in the kidney.  It is well known to make the 
headlines as doping in sports. Its main use and also value, however, is the 
treatment of anaemia associated with kidney insufficiency and other chronic 
anaemias, e.g. resulting from chemotherapies, bone marrow transplantations or 
HIV infections. The volume of the global market for EPO has been estimated to 
nearly USD 10 billion per year, and patent protection plays a key role for access 
to this market.” (Schutt, 2004)   
 
 
 Agmen, a pharmaceutical company, first cloned the EPO gene allowing its mass 
production in genetically engineered cells.  They eventually received a patent on the process.  
Then another company, TKT, created a system that allowed the EPO-synthesizing cells to divide 
twice as fast.  Agmen sued TKT arguing patent infringement, which was eventually upheld.  
Blockbuster drugs with billions of dollars at stake tell interesting stories about initial patent 
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protection for scientists and companies who initially created the new drugs, but then most 
everyone else, including the patients, are happy once the patent expires and the drug can go 
generic, saving patients much money. 
 
Benefits of Patenting Transgenic Animals 
 Designing a new transgenic animal is not easy.  For example, when making a new disease 
model, years in the lab must be spent understanding enough about the disease in humans to be 
able to mimic its formation in mice by implanting a few carefully chosen genes.  And when 
making a new transpharmer, years must be spent deciding which human protein is worth 
manufacturing in large quantities, and in proving it can be produced in mammary tissue at full 
bioactivity.  This requires large amounts of investment cash, and the investment can be risky 
depending on how far along the research has progressed.  “It is obvious that biotechnological 
advances have many uses that will benefit public health and wellness, but the research required 
to create these advances is very expensive to undertake” (Walter, 1998).  If the work is 
performed as part of a start-up company, as the project costs increase beyond the ability of the 
small company to pay, it will often seek larger pharmaceutical company as a partner to help 
shoulder the costs.  Once the transgenic animal has been successfully created, most investors 
want to protect the invention with a patent to ensure the invention generates some revenue.  So in 
this sense, patents can sometimes help facilitate the advancement of medical science by helping 
ensure more money comes back to the company to allow more advances. 
“Patents stimulate the growth of industry, and the biotechnology 
industry welcomes any patent protection it receives. Due to the 
controversial nature of patenting "life," or products intimately 
associated with life, it is necessary to pursue patent protection with 
solid grounding in patent law that is adequately suited to biological 
advances.” (Walter, 1998)   
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Negatives of Patenting Transgenic Animals 
 In some cases, scientists have argued that patenting a transgenic animal has actually 
hindered scientific research.  This was the case in the early years following the patenting of 
Oncomouse when Harvard and Dupont charged a large licensing fee for any lab to work with the 
animal (Marshall, 2002).  This allowed large relatively wealthy labs to experiment with 
Oncomouse, but left out smaller labs that could not easily afford the fee.  This seemed unfair for 
the smaller labs because they had the same technology.  This helped smaller labs because they 
were then able to do the research for the price that was right for them. As time went on these fees 
were lowered which allowed some of the smaller labs to be able to afford the price.   
 In other cases, people are concerned with the total cost of producing the animal versus how 
else that money could have been spent.  For example, should the several million dollars it took to 
create ANDi the world’s first transgenic primate who contained a jellyfish gene have been better 
spent on providing vaccines to the poor?  This question is hard to answer until the subsequent 
benefits of ANDi are more fully realized with the production of other transgenic primates that 
directly provide a benefit.  There are no guarantees in this industry, so in the end, for some cases 
it could use millions of dollars to create an animal that in the end provides no benefit to society.  
However, this gets to the heart of the debate about long term research dollars versus direct 
medical care, and if research dollars are discontinued, some diseases will not be cured. 
 In other cases, the public is worried about the escape of transgenic animals into the wild.  
For example, with AquaBounty’s Superfish some are worried they may escape their fenced in 
cage to interbreed with other wild type Salmon, passing on their genetic modification.  However, 
in this case, AquaBounty made the Superfish sterile, so they are incapable of breeding, but the 
main point of an environmental escape is always worth our planning for.  A Purdue professor 
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Bill Muir did a study on transgenic Medaka (Japanese fish) and put them in a tank with Atlantic 
salmon and the study showed that when these transgenic fish are partnered with the normal fish 
things could be catastrophic.  These professors say that other fish could become extinct because 
of the larger size of the transgenic fish and also confer an advantage in attracting mates. 
(Purdue.edu 2000)  Based on this information it is key that these animals are kept with their own 
breeds until there is further information and studies showing that this would not happen to the 
natural animals 
 Some religious leaders have a problem with patenting life because it places a price tag on 
life that should not come with a price.  This topic was covered in Chapter-3, and in the end some 
of these individuals may never be convinced regardless of the human lives saved.  Other people 
are concerned that now that animal patents are allowed, will transgenic human patents be next?  
Will we allow genetic modifications to be made to humans to make them more disease resistant?  
We currently allow genes to be inserted to treat specific genetic disorders in gene therapy, but 
genetically altering a normal human is not currently allowed.   
In any case, due to ethical problems associated with some categories of transgenic 
animals and their patenting, the industry would be better served by a more open patenting 
process with better visibility to the public.  With better visibility and information, the public 
would be better equipped to enter into discussions of transgenic ethics in full view of their 
medical benefits.   
 
FDA Guidelines 
The new patenting guidelines for transgenic animals provided by the FDA in 2009 should 
help in this process by making the process simpler and more open (FDA.gov, 2009).  “The 
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FFDCA defines "articles (other than food) intended to affect the structure or any function of the 
body of man or other animals" as drugs. An rDNA construct that is in a GE animal and is 
intended to affect the animal's structure or function meets the definition of an animal drug, 
whether the animal is intended for food, or used to produce another substance. Developers of 
these animals must demonstrate that the construct and any new products expressed from the 
inserted construct are safe for the health of the GE animal and, if they are food animals, for food 
consumption.” (FDA.gov, 2009)  This new definition provided by the FDA will greatly help 
people understand the transgender legalities.  The FDA outlined the animals that can be copied 
as generics and can be seen in the FDA Green Book. (FDA.gov, 2009)   
“The GADPTRA provides for a period of 3 years of marketing exclusivity for a 
new use of an animal drug (a use that required reports of new clinical or field 
investigations for its approval), during which time no abbreviated application for 
a generic copy may be approved for the new use.  The law provides for a period 
of 5 years of marketing exclusivity for an animal drug that has not been 
previously approved in any new animal drug application. During this period, no 
abbreviated application may be submitted. (Exception: An abbreviated application 
may be submitted after 4 years if the generic applicant claims non-infringement of 
a listed patent that is claimed for the approved product or its use.) The law also 
provides for another form of marketing exclusivity, known as patent term 
restoration. This type of exclusivity extends the period of protection by U.S. 
patent for an animal drug, or its method of use, that was approved after November 
16, 1988, to compensate for the time that was required for investigation and 
regulatory review of the animal drug prior to its approval. Patent term restoration 
is not related to the exclusivity periods described above and may overlap those 
exclusivity periods.” (FDA.gov, 2009) 
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PROJECT CONCLUSIONS 
 
A transgenic animal has been engineered to have a foreign gene inserted in its 
genome.  The foreign gene causes the animal to express characteristics that are not normally 
found in nature.  Potential applications include the ability of the animal to produce a human 
pharmaceutical in its milk, or the ability to serve as a human disease model. Transgenic animals 
can be created using pronuclear manipulation, embryonic stem cell manipulation, or nuclear 
transfer.  In pronuclear manipulation and embryonic stem cell manipulation, the transgene of 
interest is usually isolated using restriction nucleases or it can be amplified by polymerase chain 
reaction (PCR), and then inserted into an embryo using a vector system. Vector systems include 
viruses, cosmids, and plasmids. The plasmid is the most commonly used vector.  Transgenic 
technology is not efficient; most of the offspring will not contain the transgene or may be a 
chimera depending on the method used.  Thus, potential transgenic pups are typically screened 
by PCR or by Southern blot analysis to detect the presence of the transgene in the animal’s DNA. 
Transgenic animals can be divided into five main categories: disease models (that 
mimic specific aspects of a human disorder), transpharmers (that produce human 
pharmaceuticals), xenotransplanters (that produce organs for human transplants), food sources 
(for consumption), and biological models (that study the effects of specific proteins in 
vivo).  Each category was examined, weighing the benefits to society with the detriments to 
animals or the environment.  Disease models, transpharmers, and xenotransplanters, have strong 
medical benefits, however some disease models are especially prone to pain and suffering (i.e. 
Oncomouse).  To minimize this suffering strong regulations are necessary. Painkillers and 
euthanasia should be used to prevent animal suffering.  Disease models, transpharmers, and 
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xenotransplanters offer potential cures to cancer, new drug delivery methods to newborns via 
milk, and a potential solution to the human organ shortage.  Research in these categories should 
be continued since the applications have the potential to save millions of lives.  
Transgenic animal food sources are one of the most controversial categories of 
transgenic research because as they would be consumed by humans.  “Super animals” have been 
created to grow faster with less food.  Unfortunately, Superpig developed extremely serious side 
effects and had to be euthanized.  The authors believe the creation of “Super mammals” should 
only be revisited if absolutely necessary for human survival, because of the severe side effects 
exhibited in the case of Superpig.  However, Superfish have been very successful with no 
observed negative side effects.  AquaBounty’s salmon and trout had no observable deleterious 
effects and soon will be approved by the FDA for human consumption.  To ensure that 
AquaBounty’s Superfish do not breed they are sterilized; this helps ensure that delicate 
ecosystems are not affected in the event of an escape.  
The patenting of life is a controversial topic in transgenic research. The world’s first 
patented lifeform was Chakrabarty’s bacteria, engineered to consume oil slicks.  This was a very 
difficult patent to obtain, but its lead the way for the world’s first animal patent, for 
Oncomouse.  Canada does not allow the patenting of animals. Patenting allows a company to 
protect its profits which can increase their funds for other medical research.   However, patents 
can also have a negative effect on research if the fees are so high they discourage smaller labs 
from performing research.  
Based on the findings of this project, the authors of this project believe that all five major 
classes of transgenic animals should be continued with extreme caution.  In all cases, every effort 
should be made to minimize any animal suffering.  Containment procedures should be 
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implemented to prevent the introduction of a foreign species into the environment. The authors 
also believe that transgenic fish should be approved by the FDA to help fight world hunger, but 
agree that any “Super mammals” (such as Superpig) should be disallowed.  In all cases, strong 
legislative oversights should be followed to help ensure that any experiments gone wrong are 
contained and terminated.  
 
 
 
 
 
 
 
 
 
 
